General MedicationsORALStandard
KONVOMEP
OMEPRAZOLE; SODIUM BICARBONATE
Standard Dose
2MG/ML;84MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview KONVOMEP is listed in Drugs@FDA under application 213593 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient OMEPRAZOLE; SODIUM BICARBONATE Form and strength FOR SUSPENSION;ORAL - 2MG/ML;84MG/ML Sponsor AZURITY Submission history Latest submission status date: 2022-08-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview KONVOMEP is listed in Drugs@FDA under application 213593 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient OMEPRAZOLE; SODIUM BICARBONATE Form and strength FOR SUSPENSION;ORAL - 2MG/ML;84MG/ML Sponsor AZURITY Submission history Latest submission status date: 2022-08-30 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.